GlassScriptPhysician profile
Stephen Carl Abel
NPI 1033642319
$938.12
in general payments reported to CMS, 2019-2025
14 companies · $172 in 2025
The $172 reported for 2025 was less than what a typical Radiation Oncology provider received nationally (typical 2025 total: $172).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $483 · 2023: $60.96 · 2024: $221 · 2025: $172.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $455.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $454.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novocure INC. | $409.14 | 2022-2025 | Optune Gio |
| Elekta, INC. | $120.05 | 2022 | |
| Siemens Medical Solutions USA, INC. | $103.40 | 2022 | |
| Merck Sharp & Dohme LLC | $74.64 | 2024 | Keytruda |
| Novartis Pharmaceuticals Corporation | $52.02 | 2023-2024 | |
| Lilly USA, LLC | $29.57 | 2024 | Jaypirca, Retevmo, Verzenio |
| Daiichi Sankyo INC. | $24.23 | 2024 | Injectafer |
| Takeda Pharmaceuticals U.S.A., INC. | $23.34 | 2025 | Fruzaqla |
| Astrazeneca Pharmaceuticals LP | $21.35 | 2024 | |
| Pfizer INC. | $20.10 | 2024 | |
| Eisai INC. | $17.92 | 2024 | |
| Taiho Oncology, INC. | $15.18 | 2024 | |
| Regeneron Healthcare Solutions, INC. | $13.77 | 2023 | Libtayo |
| Genzyme Corporation | $13.41 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Abel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.